Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position QIAsymphony Connect set to start phased ...
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and ...
Venlo, the Netherlands, Sept. 26, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAstat-Dx syndromic testing systems and associated assays have ...
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 Connect automated ...
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its recently launched, environmentally friendlier QIAwave nucleic-acid ...
QIAGEN N.V. QGEN recently announced that it will offer its premium enzymes as standalone solutions, giving researchers and business clients the freedom to design their own tests and workflows. As a ...
The firm's CEO expects lab capital expenditures to return to normal by the second half of 2026 as the overall life science ...
Qiagen aims to help scientists and caregivers use biological samples to identify and solve problems related to DNA, RNA, and proteins, which should remain in demand even as the pandemic transitions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback